ANALIZA GUERRERO: Open Payments
NPI 1972821064 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$811 in 34 payments from 11 companies in 2025. Trend: 2023 $953 · 2024 $598 · 2025 $811
Food & beverage: $811
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $313 |
| AKEBIA THERAPEUTICS INC | 4 | $85 |
| ANI Pharmaceuticals, Inc. | 4 | $84 |
| Novo Nordisk Inc | 2 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $55 |
| Vifor Pharma, Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Ardelyx, Inc. | 1 | $34 |
| Calliditas Therapeutics US Inc. | 1 | $33 |
| Aurinia Pharma U.S., Inc. | 1 | $26 |
Products named: Vanrafia, Fabhalta, Vafseo, PURIFIED CORTROPHIN GEL, Kerendia, Veltassa, JYNARQUE, IBSRELA.
Industry payments across PA — which companies pay providers there.
